BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37138332)

  • 1. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial.
    Yang D; Hou X; Qian K; Li Y; Hu L; Li L; Han M; Yao C; Liu D
    Trials; 2023 May; 24(1):306. PubMed ID: 37138332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.
    Zhao K; Lin R; Fan Z; Chen X; Wang Y; Huang F; Xu N; Zhang X; Zhang X; Xuan L; Wang S; Lin D; Deng L; Nie D; Weng J; Li Y; Zhang X; Li Y; Xiang AP; Liu Q
    J Hematol Oncol; 2022 Mar; 15(1):22. PubMed ID: 35255929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
    Kebriaei P; Hayes J; Daly A; Uberti J; Marks DI; Soiffer R; Waller EK; Burke E; Skerrett D; Shpall E; Martin PJ
    Biol Blood Marrow Transplant; 2020 May; 26(5):835-844. PubMed ID: 31505228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
    Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
    BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.
    Soder RP; Dawn B; Weiss ML; Dunavin N; Weir S; Mitchell J; Li M; Shune L; Singh AK; Ganguly S; Morrison M; Abdelhakim H; Godwin AK; Abhyankar S; McGuirk J
    Stem Cell Rev Rep; 2020 Oct; 16(5):979-991. PubMed ID: 32740891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.
    Kurtzberg J; Prockop S; Chaudhury S; Horn B; Nemecek E; Prasad V; Satwani P; Teira P; Hayes J; Burke E;
    Biol Blood Marrow Transplant; 2020 May; 26(5):855-864. PubMed ID: 32044400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial).
    Wu X; Xia Y; Zhou O; Song Y; Zhang X; Tian D; Li Q; Shu C; Liu E; Yuan X; He L; Liu C; Li J; Liang X; Yang K; Fu Z; Zou L; Bao L; Dai J
    Trials; 2020 Jan; 21(1):125. PubMed ID: 32005282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUC-MSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial.
    Yao XY; Xie L; Cai Y; Zhang Y; Deng Y; Gao MC; Wang YS; Xu HM; Ding J; Wu YF; Zhao N; Wang Z; Song YY; Wang LP; Xie C; Li ZZ; Wan WB; Lin Y; Jin HF; Wang K; Qiu HY; Zhuang L; Zhou Y; Jin YY; Ni LP; Yan JL; Guo Q; Xue JH; Qian BY; Guan YT
    Front Neurol; 2022; 13():860083. PubMed ID: 35547390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.
    Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D
    Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.
    Zhu Y; Huang C; Zheng L; Li Q; Ge J; Geng S; Zhai M; Chen X; Yuan H; Li Y; Jia W; Sun K; Li Y; Ye T; Zhao Z; Liu H; Liu Z; Jiang H
    Stem Cell Res Ther; 2024 Apr; 15(1):122. PubMed ID: 38679727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
    Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.
    Kurtzberg J; Abdel-Azim H; Carpenter P; Chaudhury S; Horn B; Mahadeo K; Nemecek E; Neudorf S; Prasad V; Prockop S; Quigg T; Satwani P; Cheng A; Burke E; Hayes J; Skerrett D;
    Biol Blood Marrow Transplant; 2020 May; 26(5):845-854. PubMed ID: 32018062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
    Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
    Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study.
    Muroi K; Miyamura K; Okada M; Yamashita T; Murata M; Ishikawa T; Uike N; Hidaka M; Kobayashi R; Imamura M; Tanaka J; Ohashi K; Taniguchi S; Ikeda T; Eto T; Mori M; Yamaoka M; Ozawa K
    Int J Hematol; 2016 Feb; 103(2):243-50. PubMed ID: 26608364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
    Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of umbilical cord-derived mesenchymal stem cells for treatment of nineteen patients with steroid-resistant severe acute graft-versus-host disease].
    Chen GH; Yang T; Tian H; Qiao M; Liu HW; Fu CC; Miao M; Jin ZM; Tang XW; Han Y; He GS; Zhang XH; Ma X; Chen F; Hu XH; Xue SL; Wang Y; Qiu HY; Sun AN; Chen ZZ; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):303-6. PubMed ID: 22781723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.